Brind.
  1. NanoViricides, Inc. is developing NV-387, a broad-spectrum antiviral drug that targets viral infections and reduces cancer resurgence via anti-inflammatory effects like IL-6.

NanoViricides, Inc. is developing NV-387 for MPox treatment to address the continuing epidemic in Africa.

4 reports, 2 independent Updated Jul 16
Gone quiet Reached 2 outlets in its first 24 hours
Reports
4
Developments
5
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

NanoViricides, Inc. is developing NV-387 for MPox treatment to address the continuing epidemic in Africa.

Who's involved

What this event is mainly about
AfricaDemocratic Republic of the Congo

How it developed

Newest first. Tap a step to see who reported it.
  1. Border contact in Cabinda province is driving mpox risk in the Democratic Republic of the Congo.Sub-event
  2. NV-387 is being developed by NanoViricides, Inc. to treat the continuing MPox upsurge in Africa.1 source
  3. NanoViricides is seeking FDA regulatory approval for NV-387, its MPox antiviral drug.1 source
  4. NanoViricides, Inc. received ethics approval for Phase II trial.1 source
  5. Phase II clinical trials for MPox treatment are underway in the DRC.

Keep exploring

Part of

NanoViricides, Inc. is developing NV-387, a broad-spectrum antiviral drug that targets viral infections and reduces cancer resurgence via anti-inflammatory effects like IL-6. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • ACCESS NewswireWHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides SHELTON, CONNECTICUT / ACCESS Newswire / July 16, 2025 / NanoVirici
  • ACCESS NewswireAdaptive Clinical Protocol Design for Phase II MPox Clade I Treatment with a Novel Broad-Spectrum Drug NV-387 is Almost Complete, Reports NanoViricides SHELTON, CT / ACCESS Newswire / July 14, 2025 /
  • Zacks Small Cap ResearchNNVC: NanoViricides Set to Initiate Phase 2 Trial in MPox By David Bautz, PhD NYSE:NNVC NanoViricides, Inc. (NYSE:NNVC) is a clinical-stage biopharmaceutical company developing a new class of broad-s
  • Unknown outlet